Updates are available Correction dated 2024-05-30
Click to view Correction: https://doi.org/10.1038/s41467-024-48976-w
-
Authors
Limorenko, Galina
Tatli, Meltem
Kolla, Rajasekhar
Nazarov, Sergey
Weil, Marie-Theres
Schöndorf, David C.
Geist, Daniela
Reinhardt, Peter
Ehrnhoefer, Dagmar E.
Stahlberg, Henning http://orcid.org/0000-0002-1185-4592
Gasparini, Laura http://orcid.org/0000-0003-3894-9898
Lashuel, Hilal A. http://orcid.org/0000-0001-7682-8320
-
Funding
Funding for this research was provided by:
AbbVie Inc. | AbbVie Deutschland
École Polytechnique Fédérale de Lausanne
Ecole polytechnique federale de Lausanne
- License Information
-
More Information
Article History
Received: 13 April 2022
Accepted: 6 June 2023
First Online: 4 July 2023
Change Date: 30 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-024-48976-w
Competing interests
: Yes there is potential Competing Interest. HL has received funding from the industry to support research on neurodegenerative diseases, including from Merck Serono, UCB, Idorsia, and Abbvie. These companies had no specific role in the conceptualization and preparation of and decision to publish this work. HL is also the Founder and Chief Scientific Officer of ND BioSciences SA, a company that develops diagnostics and treatments for neurodegenerative diseases based on platforms that reproduce the complexity and diversity of proteins implicated in neurodegenerative diseases and their pathologies. GL and HL hold the patent application No. 22204800.1 (priority founding) for the ClearTau method. D.C.S., D.G., P.R., D.E.E., and L.G. are employees of AbbVie. M.-T.W. is a former AbbVie employee. The remaining authors have no conflicts of interest to declare.
